These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23885998)

  • 1. Nucleotide prodrugs for the treatment of HCV infection.
    Sofia MJ
    Adv Pharmacol; 2013; 67():39-73. PubMed ID: 23885998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleotide prodrugs for HCV therapy.
    Sofia MJ
    Antivir Chem Chemother; 2011 Aug; 22(1):23-49. PubMed ID: 21860070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs.
    Waheed Y; Bhatti A; Ashraf M
    Infect Genet Evol; 2013 Mar; 14():247-57. PubMed ID: 23291407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
    Gardelli C; Attenni B; Donghi M; Meppen M; Pacini B; Harper S; Di Marco A; Fiore F; Giuliano C; Pucci V; Laufer R; Gennari N; Marcucci I; Leone JF; Olsen DB; MacCoss M; Rowley M; Narjes F
    J Med Chem; 2009 Sep; 52(17):5394-407. PubMed ID: 19725579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-D-2'-α-F-2'-β-C-Methyl-6-O-substituted 3',5'-cyclic phosphate nucleotide prodrugs as inhibitors of hepatitis C virus replication: a structure-activity relationship study.
    Du J; Bao D; Chun BK; Jiang Y; Reddy PG; Zhang HR; Ross BS; Bansal S; Bao H; Espiritu C; Lam AM; Murakami E; Niu C; Micolochick Steuer HM; Furman PA; Otto MJ; Sofia MJ
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5924-9. PubMed ID: 22892115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs.
    Madela K; McGuigan C
    Future Med Chem; 2012 Apr; 4(5):625-50. PubMed ID: 22458682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule and novel treatments for chronic hepatitis C virus infection.
    Harrison SA
    Am J Gastroenterol; 2007 Oct; 102(10):2332-8. PubMed ID: 17617208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-nucleoside inhibitors of the HCV polymerase.
    Sarisky RT
    J Antimicrob Chemother; 2004 Jul; 54(1):14-6. PubMed ID: 15190019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.
    Meppen M; Pacini B; Bazzo R; Koch U; Leone JF; Koeplinger KA; Rowley M; Altamura S; Di Marco A; Fiore F; Giuliano C; Gonzalez-Paz O; Laufer R; Pucci V; Narjes F; Gardelli C
    Eur J Med Chem; 2009 Sep; 44(9):3765-70. PubMed ID: 19493593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection.
    Wyles DL
    Top HIV Med; 2010; 18(4):132-6. PubMed ID: 21107012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antiviral therapies in the management of HCV infection.
    Farnik H; Zeuzem S
    Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic monophosphate prodrugs of base-modified 2'-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication.
    Gunic E; Girardet JL; Ramasamy K; Stoisavljevic-Petkov V; Chow S; Yeh LT; Hamatake RK; Raney A; Hong Z
    Bioorg Med Chem Lett; 2007 May; 17(9):2452-5. PubMed ID: 17331721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibitors of hepatitis C virus replication.
    Neyts J
    Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatitis C virus: 25 years-old, the end?].
    Pol S
    Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future hepatitis C virus treatment: interferon-sparing combinations.
    Gane E
    Liver Int; 2011 Jan; 31 Suppl 1():62-7. PubMed ID: 21205140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and characterization of 1'-C-cyano-2'-fluoro-2'-C-methyl pyrimidine nucleosides as HCV polymerase inhibitors.
    Kirschberg TA; Mish MR; Zhang L; Squires NH; Wang KY; Cho A; Feng JY; Fenaux M; Babusis D; Park Y; Ray AS; Kim CU
    Bioorg Med Chem Lett; 2015 Mar; 25(5):1040-3. PubMed ID: 25650256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The science of direct-acting antiviral and host-targeted agent therapy.
    Pawlotsky JM
    Antivir Ther; 2012; 17(6 Pt B):1109-17. PubMed ID: 23188746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the molecular targets for new therapeutical agents in hepatitis c infection.
    Vagu C; Sultana C; Ruţă S
    Roum Arch Microbiol Immunol; 2013; 72(1):5-24. PubMed ID: 23947011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to direct antiviral agents in patients with hepatitis C virus infection.
    Sarrazin C; Zeuzem S
    Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation.
    Wohl BM; Smith AA; Jensen BE; Zelikin AN
    J Control Release; 2014 Dec; 196():197-207. PubMed ID: 25451544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.